Qianhong Pharmaceutical said at the performance briefing on October 26 that the company's QhrD106 injection program is currently in the phase IIb clinical completion stage. After completing communication with the national CDE, it will promptly advance phase III clinical and marketing application related work.

Qianhong Pharmaceutical said at the performance briefing on October 26 that the company's QhrD106 injection program is currently in the phase IIb clinical completion stage. After completing communication with the national CDE, it will promptly advance phase III clinical and marketing application related work.